ProCE Banner Activity

SOLO2: Final OS Analysis of Maintenance Olaparib in Platinum-Sensitive, Relapsed Ovarian Cancer with BRCA Mutation

Slideset Download
Conference Coverage
Maintenance olaparib increased median OS by more than 1 year vs placebo and was well tolerated over prolonged treatment duration.

Released: June 01, 2020

Expiration: May 31, 2021

No longer available for credit.

Share

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

AbbVie Inc.

AstraZeneca

Bayer Healthcare Pharma

Bristol Myers Squibb

Daiichi Sankyo, Inc.

Exelixis

GlaxoSmithKline

Ipsen Biopharmaceuticals Inc

Jazz Pharmaceuticals

Karyopharm Therapeutics

Merck Sharp & Dohme Corp.

Novartis Pharmaceuticals Corporation

Pfizer and EMD Serono